Publication: SEOM clinical guideline for the management of cutaneous melanoma (2020).
dc.contributor.author | Majem, M | |
dc.contributor.author | Manzano, J L | |
dc.contributor.author | Marquez-Rodas, I | |
dc.contributor.author | Mujika, K | |
dc.contributor.author | Muñoz-Couselo, E | |
dc.contributor.author | Pérez-Ruiz, E | |
dc.contributor.author | de la Cruz-Merino, L | |
dc.contributor.author | Espinosa, E | |
dc.contributor.author | Gonzalez-Cao, M | |
dc.contributor.author | Berrocal, A | |
dc.date.accessioned | 2023-02-09T10:43:51Z | |
dc.date.available | 2023-02-09T10:43:51Z | |
dc.date.issued | 2021-03-02 | |
dc.description.abstract | Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I-III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available. | |
dc.identifier.doi | 10.1007/s12094-020-02539-9 | |
dc.identifier.essn | 1699-3055 | |
dc.identifier.pmc | PMC8057998 | |
dc.identifier.pmid | 33651321 | |
dc.identifier.pubmedURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057998/pdf | |
dc.identifier.unpaywallURL | https://link.springer.com/content/pdf/10.1007/s12094-020-02539-9.pdf | |
dc.identifier.uri | http://hdl.handle.net/10668/17259 | |
dc.issue.number | 5 | |
dc.journal.title | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | |
dc.journal.titleabbreviation | Clin Transl Oncol | |
dc.language.iso | en | |
dc.organization | Hospital Universitario Virgen de la Victoria | |
dc.organization | Hospital Costa del Sol | |
dc.organization | Hospital Universitario Regional de Málaga | |
dc.organization | Instituto de Investigación Biomédica de Málaga-IBIMA | |
dc.organization | Hospital Universitario Virgen Macarena | |
dc.page.number | 948-960 | |
dc.pubmedtype | Journal Article | |
dc.pubmedtype | Practice Guideline | |
dc.rights | Attribution 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Adjuvant treatment metastatic treatment | |
dc.subject | Melanoma | |
dc.subject | Staging | |
dc.subject.mesh | Biopsy | |
dc.subject.mesh | Brain Neoplasms | |
dc.subject.mesh | Chemotherapy, Adjuvant | |
dc.subject.mesh | Follow-Up Studies | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Immunotherapy | |
dc.subject.mesh | Lymph Node Excision | |
dc.subject.mesh | Medical Oncology | |
dc.subject.mesh | Melanoma | |
dc.subject.mesh | Molecular Targeted Therapy | |
dc.subject.mesh | Neoplasm Staging | |
dc.subject.mesh | Proto-Oncogene Proteins B-raf | |
dc.subject.mesh | Radiotherapy, Adjuvant | |
dc.subject.mesh | Skin Neoplasms | |
dc.subject.mesh | Societies, Medical | |
dc.subject.mesh | Spain | |
dc.title | SEOM clinical guideline for the management of cutaneous melanoma (2020). | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 23 | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1